Proteinuria in diabetes: Bystander or pathway to cardiorenal disease?

Journal of the American Society of Nephrology

Volumn 21, Issue 12, 2010, Pages 2020-2027

  Karalliedde, Janaka ^a   Viberti, Giancarlo ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; TROPONIN;

CARDIOVASCULAR DISEASE; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; KIDNEY DISEASE; MICROALBUMINURIA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR;

EID: 78649811812     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010030250     Document Type: Review

References (49)

1. Marshall SM: Clinical features and management of diabetic nephropathy. In: Textbook of Diabetes, 3rd Ed., edited by Pickup JC, Williams G, Oxford, UK, Blackwell Publishing, 2003, pp 53.01-53.22
2. Trevisan R, Viberti G: Diabetic nephropathy. In: Oxford Textbook of Endocrinology and Diabetes, 1st Ed., edited by Wass JAH, Shalet SM, Oxford, UK, Oxford University Press, 2002, pp 1779-1788
3. Gnudi L, Gruden G, Viberti GC: Pathogenesis of diabetic nephropathy. In: Textbook of Diabetes, 3rd Ed., edited by Pickup JC, Williams G, Oxford, UK, Blackwell Science, 2003, pp 52:1-52:22
4. Desai M, Stockbridge N, Temple R: Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J 8: E146-E152, 2006
5. Prentice RL: Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8: 431-440, 1989 (Pubitemid 19105891)
6. Hill AB: The environment and disease: Association or causation. Proc R Soc Med 58: 295-330, 1965
7. Borch-Johnsen K, Andersen PK, Deckert T: The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28: 590-596, 1985 (Pubitemid 15017393)
8. Stadler M, Auinger M, Anderwald C, Kastenbauer T, Kramar R, Feinbock C, Irsigler K, Kronenberg F, Prager R: Long-term mortality and incidence of renal dialysis and transplantation in type 1 diabetes mellitus. J Clin Endocrinol Metab 91: 3814-3820, 2006
9. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J; ADVANCE Collaborative Group: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20: 1813-1821, 2009
10. Gerstein HC, Mann JFE, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421-426, 2001
11. Ibsen H, Olsen MH, Wachtell K, Borch- Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Snapinn SM, Wan Y, Lyle PA: Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 29: 595-600, 2006
12. Caramori ML, Fioretto P, Mauer M: Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions. Diabetes 52: 1036-1040, 2003 (Pubitemid 36384275)
13. Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient? Diabetes 49: 1399-1408, 2000
14. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR: Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55: 1832-1839, 2006
15. Karalliedde J, Ghosal R, Viberti GC: Can diabetic kidney disease develop in the absence of a history of elevated urinary albumin excretion? Diabetologia 51: [Suppl 1]: S24, 2008
16. Deckert T, Feldt-Rasmussen B, Borch- Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32: 219-226, 1989
17. Escobedo J, Rana JS, Lombardero MS, Albert SG, Davis AM, Kennedy FP, Mooradian AD, Robertson DG, Srinivas VS, Gebhart SS; BARI 2D Study Group: Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary artery disease in the BARI 2D study. Mayo Clin Proc 85: 41-46, 2010
18. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65: 2309-2320, 2004 (Pubitemid 38670018)
19. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921-927, 2004
20. Remuzzi G, Benigni A, Remuzzi A: Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116: 288-296, 2006
21. Ziyadeh FN, Hoffman BB, Han DC, Iglesias- de la Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020, 2000
22. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T: Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 54: 205-226, 2009
23. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR: Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359: 1565-1576, 2008
24. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW: 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589, 2008
25. Feldt-Rasmussen B: Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 29: 282-286, 1986
26. Stehouwer CD, Endothelial dysfunction in diabetic nephropathy: State of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 19: 778-781, 2004
27. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001 (Pubitemid 34000785)
28. S. Sandhu, N. Wiebe, Fried L, Tonelli M: Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol 17: 2006-2016, 2006
29. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361: 40-51, 2009
30. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group: Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomised, placebo-controlled trials. Lancet 372: 1394-1402, 2008
31. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group: Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomised placebo-controlled trial. Lancet 372: 1385-1393, 2008
32. Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH: Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: Three randomized trials. Ann Intern Med 151: 11-20, 2009
33. Chaturvedi N, Bilous R, Hardy R, Remuzzi G, Ruggenenti P, Viberti GC: Misleading meta-analysis: A need to look beyond the headlines. Diabet Med 24: 587-591, 2007
34. Temple R: Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282: 790-795, 1999
35. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321: 1440-1444, 2000
36. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, Widimsky J, Sareli P, Taton J, Rull J, Erdogan G, De Leeuw PW, Ribeiro A, Sanchez R, Mechmeche R, Nolan J, Sirotiakova J, Hamani A, Scheen A, Hess B, Luger A, Thomas SM; Preterax in Albuminuria Regression (PREMIER) Study Group: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: Preterax in albuminuria regression: PREMIER. Hypertension 41: 1063-1071, 2003
37. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID). N Engl J Med 358: 2433-2446, 2008
38. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553, 2008
39. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos- Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; for the ACCOMPLISH Trial investigators: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomized controlled trial. Lancet 375:1173-1181
40. Wenzel RR, Littke T, Kuranoff S, Jürgens C, Bruck H, Ritz E, Philipp T, Mitchell A; SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators: Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20: 655-664, 2009
41. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; for the ASCEND Study Group: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21: 527-535, 2010
42. Heerspink HL, Greene T, Lewis JB, Raz I, Rohde RD, Hunsicker LG, Schwartz SL, Aronoff S, Katz MA, Eisner GM, Mersey JH, Wiegmann TB; Collaborative Study Group: Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 23: 1946-1954, 2008
43. Gæde P, Vedel P, Larsen N, Jensen GV, Parving H-H, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-393, 2003 (Pubitemid 36159355)
44. Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O: Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 19: 2784-2788, 2004
45. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159-2167, 2003
46. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941-1951, 2004
47. Ruggenenti P, Iliev I, Costa GM, Parvanova A, Perna A, Giuliano GA, Motterlini N, Ene-Iordache B, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial Study Group: Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). Diabetes Care 31: 1629-1634, 2008
48. Haller H, Ritz E, Ruilope L, Rabelink T, Viberti G, for the ROADMAP Steering Committee: Prevention of microalbuminuria in type 2 diabetes (ROADMAP Trial). Diabetologia 53 [Suppl 1]: S98-S99, 2010
49. De Zeeuw D, El Nahas AM: Albuminuria: A new target for therapy? Treat the kidney to protect the heart. In: Kidney Diseases in the Developing World and Ethnic Minorities, edited by El Nahas AM, New York, Taylor & Francis, 2005, pp 191-210